The “phosphaplatin” family of compounds are the result of a rational drug development process, which resulted in advantages of tolerability and avoidance of drug resistance.
The Lead candidate, PT-112, is a novel chemical entity under clinical development, which combines a remarkable safety profile with apoptotic and immunological properties in combating cancer.
Clinical data generated to date across three studies have demonstrated single-agent anti-cancer activity and an exceptional tolerability profile.
research into the compounds' mechanism of action has revealed highly nuanced features that include the hallmark signals of immunogenic cell death induction.
Our belief is that PT-112 will play a vital role in contemporary anti-cancer care, with potential as the potential best-in-class ICD inducing agent, capable of treating both solid tumors and hematological malignancies, and can turn non-responders to Immune-oncology treatment into responders through safe and impactful combination.